In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akorn Inc.

www.akorn.com

Latest From Akorn Inc.

Supreme Court Refuses Inter Partes Review

Standards of evidence for obviousness used in US inter partes patent reviews will not be reviewed by the US Supreme Court. Nor will the court consider whether the Federal Circuit can confirm inter partes decisions without issuing an opinion.

Intellectual Property Legal Issues

Supreme Court Seems Unconvinced USPTO Should Receive Attorneys' Fees In District Court Litigation

Justices question why it took 170 years for the patent office to seek attorneys' fees from patent applicants who challenge its decisions in district court; USPTO acknowledges the delay is 'atmospherically unhelpful.'

Legal Issues Intellectual Property

FDA Warning Letter Hits Akorn’s Subpar Root Cause Investigations

Akorn has been hit with its second warning letter this year, this time for similar issues at a different site, where the US FDA found the firm failed to adequately address problems with impurities and bottle defects. The Akorn letter may also be symptomatic of a larger problem being seen by the agency in the growing number of faulty root cause investigations.  


Manufacturing Quality

Akorn Receives Second Warning Letter In Six Months

After receiving multiple Form 483s, Akorn receives yet another warning letter in the span of six months from the US Food and Drug Administration. 

Manufacturing Compliance
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Radiopharmaceuticals, Contrast Agents
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akorn Inc.
  • Senior Management
  • Raj Rai, CEO
    Duane A Portwood, CFO
    Jonathan Kafer, EVP, Sales & Mktg.
    Bruce Kutinsky, PharmD, COO
    Steve Lichter, EVP, Pharma Ops
    Randall E Pollard, Chief Accounting Officer
  • Contact Info
  • Akorn Inc.
    Phone: (800) 932-5676
    1925 West Field Ct.
    Ste. 300
    Lake Forest, IL 60045
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register